^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Mabtas (rituximab biosimilar)

    Associations

    News

    Trials
    Company:
    Intas
    Drug class:
    CD20 inhibitor
    Related drugs:
    Associations

    News

    Trials
    15d
    Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2024 --> Sep 2025
    Trial completion date • Post-transplantation
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    25d
    Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission (clinicaltrials.gov)
    P3, N=689, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting | Trial completion date: Jan 2032 --> Jan 2027
    Enrollment closed • Trial completion date
    |
    CCND1 (Cyclin D1) • CD4 (CD4 Molecule) • SOX11 (SRY-Box Transcription Factor 11)
    |
    Chr t(11;14) • SOX11 expression
    |
    clonoSEQ
    |
    Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Mabtas (rituximab biosimilar)
    3ms
    Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, City of Hope Medical Center
    New P2 trial • Combination therapy
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • nemtabrutinib (MK-1026)
    3ms
    Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2024 --> Aug 2025
    Trial completion date • Combination therapy • Surgery • Metastases
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    6ms
    NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Jun 2025 | Trial primary completion date: Mar 2025 --> Jun 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • gemcitabine • Rituxan (rituximab) • oxaliplatin • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    6ms
    Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=244, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2028 --> Sep 2027 | Trial primary completion date: Dec 2028 --> Sep 2027
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Neulasta (pegfilgrastim) • ABP 206 (nivolumab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • prednisolone
    7ms
    Pirtobrutinib With Rituximab for the Treatment of Newly Diagnosed Marginal Zone Lymphoma (clinicaltrials.gov)
    P2, N=23, Not yet recruiting, Narendranath Epperla
    New P2 trial • Combination therapy
    |
    Rituxan (rituximab) • Jaypirca (pirtobrutinib) • Mabtas (rituximab biosimilar)
    7ms
    Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma (clinicaltrials.gov)
    P1, N=32, Suspended, National Cancer Institute (NCI) | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • lenalidomide • methotrexate • ABP 206 (nivolumab biosimilar) • Mabtas (rituximab biosimilar) • methotrexate IV
    7ms
    Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2/3, N=422, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Onureg (azacitidine oral) • Mabtas (rituximab biosimilar)
    8ms
    Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (clinicaltrials.gov)
    P2, N=92, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2024 --> Mar 2028 | Trial primary completion date: Apr 2024 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • Mabtas (rituximab biosimilar)
    8ms
    Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=83, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Combination therapy • Metastases
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 expression
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Zolinza (vorinostat) • Mabtas (rituximab biosimilar)
    8ms
    Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=80, Recruiting, Mayo Clinic | N=55 --> 80
    Enrollment change
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection
    8ms
    Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma (clinicaltrials.gov)
    P3, N=600, Not yet recruiting, National Cancer Institute (NCI)
    New P3 trial
    |
    Rituxan Hycela (rituximab/hyaluronidase) • Lunsumio (mosunetuzumab-axgb) • Mabtas (rituximab biosimilar)
    9ms
    Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • bortezomib • alisertib (MLN8237) • Mabtas (rituximab biosimilar)
    9ms
    ALLIANCE A041202: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=547, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Jan 2025
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine • Belrapzo (bendamustine RTD) • Mabtas (rituximab biosimilar)
    9ms
    NCI-2023-08755: Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=0, Withdrawn, Northwestern University | N=29 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Opdivo (nivolumab) • Venclexta (venetoclax) • Rituxan (rituximab) • ABP 206 (nivolumab biosimilar) • Mabtas (rituximab biosimilar)
    9ms
    Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (clinicaltrials.gov)
    P2, N=92, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • Mabtas (rituximab biosimilar)
    9ms
    Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=70, Recruiting, National Cancer Institute (NCI) | Initiation date: Jul 2024 --> Jan 2024
    Trial initiation date
    |
    CD20 (Membrane Spanning 4-Domains A1) • PD-1 (Programmed cell death 1) • PD-L2 (Programmed Cell Death 1 Ligand 2)
    |
    CD20 expression
    |
    Rituxan Hycela (rituximab/hyaluronidase) • Lunsumio (mosunetuzumab-axgb) • Mabtas (rituximab biosimilar)
    9ms
    Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma (clinicaltrials.gov)
    P1, N=32, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • lenalidomide • methotrexate • ABP 206 (nivolumab biosimilar) • Mabtas (rituximab biosimilar) • methotrexate IV
    9ms
    NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Mar 2025 | Trial primary completion date: Jan 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • gemcitabine • Rituxan (rituximab) • oxaliplatin • Mabtas (rituximab biosimilar)
    9ms
    Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=349, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    CD20 expression • MYC translocation
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • Mabtas (rituximab biosimilar)
    9ms
    Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Jan 2025
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Mabtas (rituximab biosimilar)
    9ms
    Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Northwestern University
    New P2 trial
    |
    Opdivo (nivolumab) • Venclexta (venetoclax) • Rituxan (rituximab) • ABP 206 (nivolumab biosimilar) • Mabtas (rituximab biosimilar)
    10ms
    CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Nathan Denlinger | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    Rituxan (rituximab) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)
    10ms
    CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Nathan Denlinger
    New P1 trial • CAR T-Cell Therapy
    |
    Rituxan (rituximab) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)
    11ms
    A051701: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (clinicaltrials.gov)
    P2/3, N=363, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Mabtas (rituximab biosimilar)
    12ms
    ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P3, N=488, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2023
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD20 (Membrane Spanning 4-Domains A1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RUNX1 (RUNX Family Transcription Factor 1) • IGH (Immunoglobulin Heavy Locus) • ETV6 (ETS Variant Transcription Factor 6) • CD4 (CD4 Molecule) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • etoposide IV • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    almost1year
    Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2024 --> Sep 2024
    Trial completion date • Post-transplantation
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Mabtas (rituximab biosimilar)
    1year
    Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=70, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: Mar 2026 --> Oct 2026 | Initiation date: Oct 2023 --> Jul 2024 | Trial primary completion date: Mar 2026 --> Oct 2026
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • PD-1 (Programmed cell death 1) • PD-L2 (Programmed Cell Death 1 Ligand 2)
    |
    CD20 expression
    |
    Rituxan Hycela (rituximab/hyaluronidase) • Lunsumio (mosunetuzumab-axgb) • Mabtas (rituximab biosimilar)
    1year
    Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov)
    P1, N=54, Recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2023 --> Jun 2025 | Trial primary completion date: Sep 2023 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    CD20 positive
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)
    over1year
    NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2023 --> Jan 2024 | Trial primary completion date: Jun 2023 --> Jan 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • gemcitabine • Rituxan (rituximab) • oxaliplatin • Mabtas (rituximab biosimilar)
    almost2years
    Effectiveness and Safety of Rituximab Biosimilar in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results from a Prospective, Multicentre, Real-World Registry Study (ASH 2022)
    This real-world study evaluated the safety and efficacy outcomes of rituximab biosimilar (Mabtas) plus chemotherapy (R-chemo) in Indian patients with B-cell NHL or CLL...Overall, R-chemo was well-tolerated. Conclusion s : Rituximab biosimilar based chemotherapy was effective and safe in real-world clinical practice as the first-line treatment for B-cell NHL and CLL.
    Clinical • Real-world evidence
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Mabtas (rituximab biosimilar)